logo

For the Inventor, By the Inventor

Hanover, Germany

Hans Liepmann

USPTO Granted Patents = 15

Average Co-Inventor Count = 5.2

ph-index = 3

Forward Citations = 64(Granted Patents)


Company Filing History:

goldMedal15 out of 92 
 
Kali-chemie Pharma Gmbh
 patents

Years Active: 1979-1987

Loading Chart...
15 patents (USPTO):Explore Patents
1. 4649137 - 2-acylaminomethyl-1,4-benzodiazepine compounds, the preparation thereof, (1987-03-10),
2. 4594436 - Isomeric 2-chloromethyl-1,4-benzodiazepine or (1986-06-10),
3. 4533662 - 2-Acylaminomethyl-1,4-benzodiazepine compounds and analgesic use (1985-08-06),
4. 4508716 - [1,2]-Fused 1,4-benzodiazepine compounds, process for their preparation (1985-04-02),
5. 4505908 - 7-Bromo-5-(2-halophenyl)-1H-2,3-dihydro-1,4-benzodiazepine (1985-03-19),
6. 4497740 - 2-Azidomethyl-1,4-benzodiazepine compounds (1985-02-05),
7. 4482548 - Analgesic pharmaceutical compositions containing 5-phenyl-1,4-benzo (1984-11-13),
8. 4402981 - N.sub.1 -Acyl-N.sub.2 -phenyl-diaminopropanols and pharmaceutical (1983-09-06),
9. 4382030 - 2-Acylaminomethyl-1,4-benzodiazepine derivatives and their salts, (1983-05-03),
10. 4338314 - [1,2]Anellated-7-phenyl-1,4-benzodiazepine and pharmaceutical (1982-07-06),
11. 4325957 - 2-Acylaminomethyl-1,4-benzodiazepine derivatives and their salts and (1982-04-20),
12. 4271193 - N1-Benzoyl-N2-phenyldiaminopropanols and pharmaceutical compositions (1981-06-02),
13. 4191770 - N.sub.1 -acyl-N.sub.2 -phenyldiaminopropanols and pharmaceutical (1980-03-04),
14. 4177287 - Pharmaceutical compositions of N.sub.1 -acyl-N.sub.2 (1979-12-04),
15. 4170649 - 1,4-Benzodiazepine derivatives, pharmaceutical compositions thereof, and (1979-10-09),

Title: An Overview of Hans Liepmann: A Skilled Innovator in the Field of Pharmaceuticals

Introduction:

In the realm of pharmaceutical innovations, Hans Liepmann is a prominent figure whose contributions have significantly advanced the development of therapeutic compounds. Hailing from Hanover, Germany, Liepmann has amassed an impressive portfolio of 15 patents. This article delves into his latest patents, career highlights, collaborations, and highlights the impact of his work in the pharmaceutical industry.

Latest Patents:

Hans Liepmann's recent patents revolve around 2-acylaminomethyl-1,4-benzodiazepine compounds, their preparation, and their potential applications. These compounds, described by their general formula I, demonstrate notable pharmacological properties, particularly in the realm of analgesics. The patented compounds possess diverse molecular structures, with varying functional groups and substituents that contribute to their therapeutic effects. Moreover, Liepmann's patents also encompass isomeric 2-chloromethyl-1,4-benzodiazepine compounds, which exhibit neuroleptic properties.

Career Highlights:

Throughout his illustrious career, Liepmann has excelled as a researcher and innovator in the pharmaceutical field. Currently associated with Kali-Chemie Pharma GmbH, his valuable contributions have led to the development of various groundbreaking compounds. With an exceptional track record of inventions and patents, Liepmann has significantly advanced the understanding and application of benzodiazepine compounds in pharmaceutical research.

Collaborations:

Collaboration plays a crucial role in the world of innovation, and Hans Liepmann has successfully partnered with fellow industry experts. Notably, he has worked closely with esteemed colleagues such as Horst Zeugner and Wolfgang Milkowski. These collaborations have fostered meaningful exchanges of ideas and expertise, leading to successful research outcomes and groundbreaking developments in the field of pharmaceuticals.

Conclusion:

Hans Liepmann's dedication and innovation have contributed extensively to the pharmaceutical field. His 15 patents, particularly for his work on benzodiazepine compounds, demonstrate his expertise and commitment to advancing therapeutic possibilities. Through his collaborations, Liepmann has also successfully engaged with other experts, enriching the progress in the industry. As a skilled innovator at Kali-Chemie Pharma GmbH, Liepmann continues to play a crucial role in shaping the future of pharmaceutical research and development.

Please note that the information provided in this article is based on the given data and might not represent the entire scope of Hans Liepmann's work. For more detailed and accurate information, it is recommended to refer to official sources and publications related to his work and patents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…